Space
A spec-locked, sole-source space-and-defense subsystem roll-up riding Golden Dome and OBBBA tailwinds at ~50% growth — but it is a leveraged (2.1x D/E) PE-sponsor exit story with a live material weakness, ~$680M of floating-rate debt, and a still-rich ~34x forward EV/Adj-EBITDA; the 58% drawdown is a Trive-Capital supply unwind, not a thesis break. WATCHING (coverage note: this is fundamentally a defense prime-supplier — see exclusion flag).
Research
The verdict
A spec-locked, sole-source space-and-defense subsystem roll-up riding Golden Dome and OBBBA tailwinds at ~50% growth — but it is a leveraged (2.1x D/E) PE-sponsor exit story with a live material weakness, ~$680M of floating-rate debt, and a still-rich ~34x forward EV/Adj-EBITDA; the 58% drawdown is a Trive-Capital supply unwind, not a thesis break. WATCHING (coverage note: this is fundamentally a defense prime-supplier — see exclusion flag).
Karman Holdings Inc. (d/b/a Karman Space and Defense; HQ Huntington Beach, CA; NYSE: KRMN) is a mission-critical subsystem and component supplier to space and defense prime contractors. It designs, develops and manufactures three product families — Payload Protection & Deployment Systems, Aerodynamic Interstage Systems, and Propulsion & Launch Systems — sold into four end-markets: Hypersonics & Strategic Missile Defense, Tactical Missiles & Integrated Defense Systems, Space & Launch, and (new in 2026) Maritime Defense. It supplies >80 prime contractors across >130 active programs, and estimates no single program exceeded ~11–12% of revenue in 2025–Q1'26.
Business model. It is a "concept-to-production," vertically integrated, buy-build-integrate roll-up: Karman began with four core acquisitions and continues to acquire subscale specialist shops, integrate them, and cross-sell into a broadened program base. Revenue is recognized over time (cost-input method) under ASC 606 across fixed-price, T&M and cost-plus contracts; payment terms ~45 days.
Customers / suppliers / competitors. End customers are U.S. government programs (Army, Navy, Air Force, Missile Defense Agency, NASA) reached through the primes plus some commercial space; substantially all customers are U.S.-based. Competitors are sub-integrated "build-to-print" piece-part shops with "less differentiated IP" — Karman positions above them on technical differentiation and early-design entanglement.
Contract structure / key terms. Backlog $1.027B at Q1'26 (vs $636M a yr ago); remaining performance obligations (RPO) $723.3M, of which ~42% recognized in remaining-2026, 24.1% in 2027, 33.9% thereafter. The "backlog" figure includes LTAs and authorizations beyond contracted RPO (it was rebranded from "funded backlog" — a soft point flagged in Lens 10). ~1,400 employees (300 engineers), non-union.
Upstream inputs → Karman → end customer. Karman is itself a mid-stream supplier: it buys raw materials (composites, metals, energetics/solid propellant), labor and subcontracted content, converts them into highly engineered subsystems, and ships to prime contractors who integrate them into missiles, interceptors, launch vehicles and naval platforms for the DoW/MDA/NASA end customer.
Named stakeholders along the chain:
Chokepoints / single-source dependencies. Karman's own risk disclosure: "if critical components or raw materials … become scarce or unavailable, then we may incur delays" — i.e. it carries upstream material/energetics dependency. Conversely, Karman holds significant sole-/single-source positions to its primes (Lens 3) — a chokepoint in its own favor. Manufacturing is concentrated in physical plants across CA/WA/OR/UT/MS/PA/SC/AL, exposed to facility/physical risk.
The moat is real and structural, and it is the bull case.
One reportable segment — the CODM reviews consolidated results; the four end-markets are revenue disaggregation only. So there is no segment EBIT/EBITDA split to source; segment-level operating income is n/a — not disclosed.
Revenue by end-market (``):
| End-market | Q1'26 ($k) | Q1'25 ($k) | YoY | FY2025 share |
|---|---|---|---|---|
| Hypersonics & Strategic Missile Defense | 35,688 | 30,056 | +18.7% | 31.7% |
| Tactical Missiles & Integrated Defense | 45,260 | 36,197 | +25.0% | 31.5% |
| Space & Launch | 43,854 | 33,871 | +29.5% | ~36.8% |
| Maritime Defense (new, Seemann) | 26,408 | — | n/m | — |
| Total revenue | 151,210 | 100,124 | +51.0% | 100% |
Trend & cause. Growth is broad-based and accelerating: Tactical driven by "continued adoption of advanced drone and loitering-munitions technologies and increased GMLRS production"; Hypersonics by "strategic programs"; Space & Launch by "timing of orders for critical content supporting both legacy and emerging launch providers"; Maritime entirely from the Seemann acquisition (submarine + LCAC). Note: ~26% of the Q1 +51% is inorganic (Maritime $26.4M was zero a year ago); organic growth is therefore a still-strong ~25% but the headline overstates the organic engine.
The print vs. the tape is the whole story. Headline numbers were strong; the stock fell >10%.
GAAP P&L (``):
Beat/miss. Despite the strong revenue, EPS missed: $0.06 GAAP vs Street ~$0.08–0.11; the consensus appears to have been set near the Adjusted-EPS line, and integration/transaction costs ($2.3M transaction + $2.5M other non-recurring + $1.6M legal settlement) pulled the optics down. Adj-EBITDA margin slipped slightly (29.6% vs 30.3% a yr ago) on integration drag.
Guidance. FY2026: revenue $720–735M (~+53–56%) and Adjusted EBITDA $208.5–219.5M. Implies ~29–30% Adj-EBITDA margin sustained.
Balance-sheet flags (the real watch-items):
Market reaction. Down >10% on the print, part of a slide from ~$118 (Jan) to ~$49.58 (June 11) — a −58% drawdown from the 52-wk high. What was priced in: a near-flawless growth-plus-margin compounder; the miss + a sponsor-supply overhang (Lens 8) broke that.
No transcripts on disk (transcripts/ empty). From : the **Q1 2026 call (May 12)** was titled by Investing.com as "shows strong growth," and Barchart's pre-call piece framed the central question as **"whether the backlog can actually convert"** — i.e. the market's focus has shifted from *can they grow?* to *can they convert $1.0B of backlog to cash without the leverage and integration drag eating it?*. Management's stated KPI set is telling: they steer on **Revenue, Backlog, EBITDA, Adjusted EBITDA, Adjusted EBITDA Margin** — note **GAAP EPS and free cash flow are conspicuously absent** from the headline KPI dashboard. Tone shift over the last ~12 months: from IPO-era "secular tailwind / Golden Dome" story to a more defensive "backlog conversion + integration discipline" posture as the stock de-rated. for sentiment; recurring phrases: "mission-critical," "sole-source," "concept-to-production," "buy-build-integrate."
Peers are premium aerospace/defense subsystem & engineered-component compounders. Multiples are `` (mixed LTM/forward, dates noted) — treat the absolute levels as approximate; the provenance trap here is a stale-numerator LTM EV/EBITDA.
| Company | Ticker | Mkt cap | EV/EBITDA | Note / source |
|---|---|---|---|---|
| Karman Holdings | KRMN | ~$6.57B | ~50x LTM / ~34x fwd | GuruFocus shows ~94x LTM — stale/mismatched, do not use |
| HEICO | HEI | n/a | ~31.7x | Premium engineered-component compounder |
| Loar Holdings | LOAR | n/a | ~30x fwd | Closest analog (recent IPO, roll-up) |
| Howmet Aerospace | HWM | n/a | ~44.5x | Large-cap A&D materials |
| TransDigm / Curtiss-Wright (ref.) | TDG / CW | n/a | ~20–30x range | The premium-A&D band |
P/E, dividend yield, 5-yr avg ROE for KRMN: mostly n/a — KRMN IPO'd Feb 2025 (no 5-yr public history); it pays no dividend; trailing GAAP P/E is distorted by amortization (GAAP net income only $17.4M FY2025 on a ~$6.6B cap ≈ ~380x trailing GAAP P/E — not a meaningful figure for a roll-up).
EV/EBITDA reconciliation: EV = $6.57B mkt cap + $0.856B total debt − $0.074B cash = ~$7.35B. Against FY2025 Adj-EBITDA $145.3M → EV/AdjEBITDA(LTM) ≈ 50.6x. Against FY2026 guided Adj-EBITDA midpoint $214M → EV/AdjEBITDA(fwd) ≈ 34.3x. Verdict on valuation: ~34x forward is Howmet-tier, a clear premium to HEICO/Loar (~30–32x) despite higher leverage and a live material weakness — the de-rating from ~$118 took it from "priced for perfection" to "priced for very-good." The widely-quoted 94x is an LTM artifact and should not anchor the view.
KRMN has <18 months of trading history (IPO 2026-02-14 at $22.00), so the ">5% moves over 5 years" is compressed into one year — and the pattern is unusually clean:
What the market actually reacts to for this name: (1) defense-budget/program headlines (Golden Dome up, budget delays down — note Golden Dome spending was held at OMB in Feb 2026 ); (2) sponsor-supply / lockup events (the dominant 2026 driver); (3) the EPS-vs-Adjusted optics gap. Earnings beats on revenue have NOT protected it — the float and the GAAP-EPS line dominate.
n/a (Item 12 incorporated by reference to the proxy; insider-transactions.csv absent). Trive Capital (sponsor) owned ~56% post-IPO and is actively selling down via the secondary — alignment is shifting from sponsor-control to public float.Acting as a forensic analyst. The accounting is not fraudulent on this read, but it carries the classic roll-up + percentage-of-completion + leverage risk cluster, and one hard disclosed flag:
Regulatory findings (required sub-section):
Built bottom-up from FY2025 actuals + FY2026 guidance. No forecast.ts create in watchlist mode (per skill) — the base call is stated for the record only.
Historical (``): Revenue 2023 $280.7M → 2024 $345.3M (+23%) → 2025 $471.5M (+36.6%). Adj-EBITDA 2023 $81.9M → 2024 $106.1M → 2025 $145.3M (30.8% margin). GAAP net income 2025 $17.4M; GAAP diluted EPS FY2025 ≈ $0.14.
FY2026 anchor: guidance revenue $720–735M, Adj-EBITDA $208.5–219.5M.
GAAP EPS, three fiscal years forward (FY2026E / FY2027E / FY2028E):
Base call (record only, not logged): KRMN FY2026 Adjusted EBITDA ≥ $208M (low end of guide), p≈0.70 — guidance just reaffirmed with the Q1 print; the risk is below-guide on margin, not revenue.
Bull case. A spec-locked, sole-source subsystem supplier on >130 funded programs with no single-program concentration, growing ~50% (≈25% organic), at ~30% Adjusted-EBITDA margins, sitting directly under the two largest defense-spending tailwinds of the decade — Golden Dome ($175–185B, $151B SHIELD IDIQ ceiling, Karman already positioned) and OBBBA ($150B incremental through FY2029). Backlog $1.0B and RPO $723M give multi-year visibility; the buy-build-integrate playbook (Loar-style) compounds the program base. After a −58% drawdown driven by supply (sponsor exit), it trades ~34x forward — a premium, but no longer a bubble — with analysts at $97–114 (≈2x spot) still Overweight/Buy.
Bear case (permanent-impairment vectors). (1) Leverage + cash conversion: $855M debt / 2.1x D/E, floating-rate, with operating cash flow near zero and contract assets ballooning — if backlog doesn't convert to cash, the levered model is fragile to a rate up-tick or a single EAC reset. (2) Material weakness → restatement risk under a brand-new CEO. (3) Monopsony customer + budget risk: one buyer (DoW); Golden Dome funding already saw OMB delays, and the program could be de-scoped or stretched — the entire premium multiple rests on a political appropriations cycle. (4) Sponsor overhang persists: Trive still holds a large stake post-secondary; further selling caps upside. Pre-mortem (18 mo out, thesis broke): Golden Dome funding slipped right; an acquired business missed its EAC and forced an intangible write-down + a control-remediation restatement; rates ticked up and interest ate the Adj-EBITDA growth; the stock re-rated to HEICO's ~30x on lower numbers. Are multiples too high? At ~34x fwd vs HEICO/Loar ~30–32x, with higher leverage and an open material weakness — modestly, yes; the de-rating fixed the worst of it but didn't make it cheap.
Contrarian view (what the market is refusing to see): The −58% move trained holders to read KRMN as "broken," but the break was mechanical float-doubling, not a deterioration in the franchise — backlog and guidance went up through the drawdown. The real, under-discussed risk is the opposite of the price action: it's the cash-conversion + leverage + control-weakness triangle, not the demand story, that could actually impair this business. The market is selling the right stock for the wrong reason.
Dismantling the bull case. What structurally breaks the model: Karman doesn't sell to end customers — it sells through primes into government-funded programs, so its revenue is doubly derivative: a prime can in-source, a program can be cut, and an appropriation can slip (Golden Dome already stalled at OMB ). Revenue concentration: "no single program >12%" sounds diversified, but the growth is concentrated in a handful of marquee missile/hypersonic/Golden-Dome programs whose funding is political. Why the moat may be weaker than bulls think: spec-lock protects legacy content, but the high-growth next-gen wins are recompeted and Karman is the incumbent subsystem shop, not the prime — its pricing power is capped by FAR/cost-plus economics, not TransDigm-style sole-source-to-a-commercial-aftermarket pricing. Most dangerous competitor bulls underestimate: not another small shop, but the primes themselves vertically integrating (and well-funded new defense entrants), eroding the "buy" side of make-vs-buy. Worst capital-allocation / governance: a PE sponsor (Trive) that built the platform on debt, IPO'd it, and is selling into the public while leaving a 133M-share company with an unremediated material weakness and an ISP earnout it already missed. Assumptions that must hold for today's price: (i) ~30% Adj-EBITDA margins survive integration; (ii) backlog converts to cash, not just contract assets; (iii) Golden Dome funds roughly on schedule; (iv) rates don't rise. If growth disappoints 20–30%: at ~34x forward with 2.1x leverage, a deceleration to ~20% with flat margins re-rates it toward ~25x on lower EBITDA — another 30–40% downside from $49.58 is entirely plausible. Single permanent-impairment scenario: an EAC restatement tied to the material weakness, on a levered balance sheet, during a Golden Dome funding pause — low-probability, high-severity, and the one that would break it.
The only credible bet on FULL (both-stages) reuse besides SpaceX — a metallurgy/physics moat the others ducked — but it is a single-vehicle, zero-revenue, zero-flights company whose entire value is gated on one un-flown second stage surviving reentry; WATCHING, not investable, until Nova reaches orbit and the upper stage comes home intact.
A genuine launch-and-connectivity monopoly wrapped inside an unprofitable $2T+ aspiration stock — Starlink is the real business, but at ~110x sales the market is paying for Mars, orbital AI data centers, and a $60B Cursor bet that aren't earnings yet.
A $20M-revenue EO manufacturer trading like a $1B growth story on a 200% YTD re-rate — the cost-per-satellite edge and Tether-backed balance sheet are real, but the price already discounts a Merlin success that hasn't launched, and three customers are half the revenue.